Integrated case-based management of CKD in T2DM
LOGIN/REGISTER NOW TO ACCESS THE ACTIVITY!
Introduction
Learning objectives
About our expert
Introduction
Many people with type 2 diabetes (T2DM) are unaware of their increased risk of developing chronic kidney disease (CKD) and its implications for their future health.
CKD affects ~40% of people with T2DM and it is the most common cause of kidney failure requiring dialysis or transplant globally. This can shorten the lifespan by up to 16 years compared to the general population.
CKD affects ~40% of people with T2DM and it is the most common cause of kidney failure requiring dialysis or transplant globally. This can shorten the lifespan by up to 16 years compared to the general population.
Learning objectives
You will learn:
- Benefits of early recognition of kidney disease in type 2 diabetes (T2DM) for improving cardiovascular outcomes
- Reasons why albuminuria is both an important biomarker and a treatment target in patients with T2DM
- Multifactorial drivers of chronic kidney disease (CKD) progression in T2DM and their implications for medical management
- Clinical evidence regarding finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, and international guideline recommendations on its use for the treatment of CKD and T2DM
About our expert
Dr Alkesh Magan
Endocrinologist, Specialist Physician
Sandton Mediclinic, Johannesburg
Associate Professor Feziwe Bisiwe
Nephrologist, Specialist Physician
Head of Nephrology, University of the Free State, Bloemfontein
To access this activity please login or register.
Activity Content
📝 START Questionnaire: Integrated case-based management of CKD in T2DM
You don't currently have access to this content